Meeting
2020 ASCO-SITC Clinical Immuno-Oncology Symposium
Efficacy and toxicities of immune checkpoint inhibitors (ICIs) in advanced melanoma: A single institution experience.
Authors
Karim Welaya
Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY
Karim Welaya, Andrea M. Baran, Manidhar Reddy Lekkala, Deepak M. Sahasrabudhe
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Breast and Gynecologic Cancers,Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Hematologic Malignancies
Sub Track
Immune Checkpoints and Stimulatory Receptors
Citation
J Clin Oncol 38, 2020 (suppl 5; abstr 59)
Abstract #
59
Poster Bd #
C6
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Efficacy of immune checkpoint inhibitor (ICI) rechallenge in advanced melanoma patients responders to a first course of ICI: A multicenter, national, retrospective study of the French group of skin cancers (GCC).
First Author: Charlee Nardin
Poster
2023 ASCO Annual Meeting
Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: An AGEO European Cohort.
First Author: Lorenzo Pilla
Poster
2020 ASCO Virtual Scientific Program
Estimating treatment-free survival (TFS) over extended follow-up in patients (pts) with advanced melanoma (MEL) treated with immune-checkpoint inhibitors (ICIs): Five-year follow-up of CheckMate 067.
First Author: Meredith M. Regan
Poster
2023 ASCO Annual Meeting
Time-dependent efficacy of immune checkpoint inhibitors in the treatment of metastatic cancers: A meta-analysis.
First Author: Thierry Landre